These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 30875495)

  • 21. Non-alcoholic fatty liver disease and the statins treatment.
    Dima A; Marinescu AG; Dima AC
    Rom J Intern Med; 2012; 50(1):19-25. PubMed ID: 22788090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dyslipidemia in patients with nonalcoholic fatty liver disease.
    Chatrath H; Vuppalanchi R; Chalasani N
    Semin Liver Dis; 2012 Feb; 32(1):22-9. PubMed ID: 22418885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Non-alcoholic liver disease - diagnosis and treatment].
    Sarosiekjeznach-Steinhagen A; Ostrowska J; Czerwonogrodzka-Senczyna A; Boniecka I
    Pol Merkur Lekarski; 2017 Nov; 43(257):237-242. PubMed ID: 29231919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-alcoholic fatty liver disease and dyslipidemia: An update.
    Katsiki N; Mikhailidis DP; Mantzoros CS
    Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statins Are Underused in Women With NAFLD After Cardiovascular Events Compared With Matched Control Subjects.
    Shang Y; Hagström H
    Clin Gastroenterol Hepatol; 2023 May; 21(5):1359-1361.e2. PubMed ID: 35339670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Under-prescription of statins in patients with non-alcoholic fatty liver disease.
    Del Ben M; Baratta F; Polimeni L; Pastori D; Loffredo L; Averna M; Violi F; Angelico F
    Nutr Metab Cardiovasc Dis; 2017 Feb; 27(2):161-167. PubMed ID: 27914698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease.
    Lonardo A; Ballestri S; Targher G; Loria P
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):629-50. PubMed ID: 25327387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.
    Ahsan F; Oliveri F; Goud HK; Mehkari Z; Mohammed L; Javed M; Althwanay A; Rutkofsky IH
    Cureus; 2020 Sep; 12(9):e10446. PubMed ID: 33072455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk.
    Ballestri S; Nascimbeni F; Baldelli E; Marrazzo A; Romagnoli D; Lonardo A
    Adv Ther; 2017 Jun; 34(6):1291-1326. PubMed ID: 28526997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?
    Papademetriou M; Athyros VG; Geladari E; Doumas M; Tsioufis C; Papademetriou V
    Curr Vasc Pharmacol; 2018; 16(3):254-268. PubMed ID: 28676027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017].
    Nan YM; Fu N; Li WC; Kong LL; Yuan XW; Zhang SY; Liu LD; Lu Y; Cui LY
    Zhonghua Gan Zang Bing Za Zhi; 2017 Sep; 25(9):687-694. PubMed ID: 29108191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statins for the Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.
    Dai W; Xu B; Li P; Weng J
    Am J Ther; 2023 Jan-Feb 01; 30(1):e17-e25. PubMed ID: 36608070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugs.
    Skubic C; Drakulić Ž; Rozman D
    Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):831-841. PubMed ID: 29969922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: from bedside to bench and back.
    Yilmaz Y; Colak Y; Kurt R; Senates E; Eren F
    Tumori; 2013; 99(1):10-6. PubMed ID: 23548993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statins decrease overall mortality and cancer related mortality but are underutilized in NAFLD: a longitudinal analysis of 12,538 individuals.
    Ng CH; Teng ML; Chew NW; Chan KE; Yong JN; Quek J; Tan DJH; Lim WH; Lee GSJ; Wong J; Kaewdech A; Huang DQ; Wang J; Chan MY; Noureddin M; Siddiqui MS; Sanyal A; Muthiah M
    Expert Rev Gastroenterol Hepatol; 2022 Sep; 16(9):895-901. PubMed ID: 36036200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Natural Course of Non-Alcoholic Fatty Liver Disease.
    Calzadilla Bertot L; Adams LA
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.